Neutralization of inhibitory pathways in lymphocytes

Patent metadata

Field	Value
Publication number	US-10711063-B2
Application number	US-201515511778-A
Country	US
Kind code	B2
Filing date	Sep 15, 2015
Priority date	Sep 16, 2014
Publication date	Jul 14, 2020
Grant date	Jul 14, 2020

Abstract

The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

First claim

The invention claimed is:

1. A method of treating a cancer in a human patient, the method comprising administering to the patient an effective amount of each of: (a) an antibody that neutralizes human NKG2A, and (b) an antibody that neutralizes human PD-L1, wherein the antibody that neutralizes human NKG2A comprises the CDR1, CDR2 and CDR3 domains of a heavy chain having the sequence set forth in any one of SEQ ID NOS: 4-8, and the CDR1, CDR2 and CDR3 domains of a light chain having the sequence set forth in SEQ ID NO: 9 and the antibody that neutralizes human PD-L1 is selected from nivolumab, lambrolizumab, pembrolizumab, atezolizumab, or pidlizumab.

2. The method of claim 1 , wherein at least two doses of the antibody that neutralizes human NKG2A are administered in an amount effective to achieve a continuous blood concentration of anti-NKG2A antibody of at least 10 μg/ml for at least one week following administration thereof.

3. The method of claim 2 , wherein the method comprises at least one administration cycle, wherein for each cycle, two, three or four doses of the antibody that neutralizes human NKG2A are administered and two, three or four doses of the antibody that neutralizes human PD-L1 are administered.

4. The method of claim 1 , wherein the antibody that neutralizes human NKG2A and the antibody that neutralizes human PD-L1 are formulated for separate administration and are administered concurrently or sequentially.

5. The method of claim 1 , wherein the antibody that neutralizes human NKG2A and the antibody that neutralizes human PD-L1 are formulated in a single formulation.

6. The method of claim 1 , wherein the antibody that neutralizes human NKG2A and the antibody that neutralizes human PD-L1 are administered on the same day.

7. The method of claim 1 , wherein the cancer is a solid tumor.

8. The method of claim 1 , wherein the cancer is hematological tumor.

9. The method of claim 7 , wherein the cancer is selected from the group consisting of lung cancer, renal cell carcinoma (RCC), melanoma, colorectal cancer, and ovarian cancer.

10. The method of claim 1 , wherein the cancer is an HLA-E-expressing cancer.

11. The method of claim 1 , wherein said antibody that neutralizes human NKG2A is a non-depleting antibody.

12. The method of claim 11 , wherein said antibody is IgG4 antibody, wherein said antibody lacks an Fc domain or wherein said antibody comprises an Fc domain that is modified to reduce binding between the Fc domain and an Fey receptor.

13. The method of claim 3 , wherein the administration cycle comprises a period of eight weeks.

Assignees

• Innate Pharma

Inventors

• Andre Pascale
• Blery Mathieu
• Paturel Carine
• Wagtmann Nicolai

Classifications

• C07K16/2827

  against B7 molecules, e.g. CD80, CD86 · CPC title

• A61K39/39558 Primary

  against tumor tissues, cells, antigens · CPC title

• C07K16/2818 Primary

  against CD28 or CD152 · CPC title

• C07K16/2803 Primary

  against the immunoglobulin superfamily · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title